Plain-English translation of NCT07236762 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cell therapy called YTS109 for people with autoimmune diseases that have not responded well to standard treatments. The study will give about 18 adults a single infusion of YTS109 cells and carefully monitor them to see if the treatment is safe and whether it helps control their disease. Researchers want to understand how this new treatment works in the body and what side effects, if any, it might cause.
Some people with autoimmune diseases like lupus or Sjögren's syndrome don't get better even after trying multiple standard medications. This trial exists to explore whether this new cell-based approach could offer hope to patients whose disease keeps coming back or hasn't improved despite current treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will come to Bengbu Third People's Hospital to receive a single infusion of YTS109 cells. The research team will start with a low dose and may increase it over time as they monitor your safety. You will have follow-up visits and blood tests to check for any side effects and to see whether the treatment is helping control your autoimmune disease symptoms.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China